Biochemical derangements related to metabolic syndrome in epileptic patients on treatment with valproic acid

VPA treatment increased the risk factors for the development of metabolic syndrome such as hyperinsulinemia, insulin resistance and oxidative stress. However VPA treatment corrected the dyslipidemia of epileptic patients.